<DOC>
	<DOCNO>NCT01502631</DOCNO>
	<brief_summary>The purpose research study gather scientific information effectiveness study drug , SUN13837 Injection , compare placebo ( inactive substance ) subject acute spinal cord injury .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Pharmacokinetics SUN13837 Injection Adult Subjects With Acute Spinal Cord Injury ( ASCI )</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>1 . Acute traumatic injury cervical neurological spinal cord follow : 1 . American Spinal Injury Association Impairment Scale A level injury either C4 , C5 , C6 , C7 ( C4 , subject must least 1 point motor activity within ZPP inclusive C5 T1 ) . In addition , AIS A subject may include ALL follow present 1 ) caudal intact sensory segment ( pinprick light touch ) C3 , 2 ) least one side ( right left ) intact pinprick light touch sensation C4 dermatome , AND 3 ) least 1 point motor activity within ZPP inclusive C5 T1 2 . American Spinal Injury Association Impairment Scale B C neurological level injury either C3 , C4 , C5 , C6 , C7 , C8 AND total LEMS 5 few motor point 2 . Closed single traumatic spinal cord injury occur within 12 hour first dose 3 . Male female AIS A subject ≥ 16 ≤ 80 year male female cervical AIS B C subject ≥16 ≤70 year 4 . Females childbearing potential male must agree maintain adequate contraception first 35 day study 1 . Unable obtain informed consent ( either subject subject 's LAR ) 2 . Women breastfeed ( unwilling stop first 35 day study ) pregnant 3 . Coma significant impairment level consciousness interfere performance interpretation protocol specify assessment 4 . Any disease , concomitant injury , condition interferes performance interpretation protocol specify assessment 5 . Unable , determined investigator , unwilling discontinue use potent Pglycoprotein ( Pgp ) inhibitor first 35 day study 6 . Unable , determined investigator , unwilling discontinue use potent cytochrome P450 ( CYP ) 3A4/5 inducer first 35 day study 7 . Renal compromise ( serum creatinine great 1.5 time age sexappropriate upper limit normal [ ULN ] ) screen first dose study drug 8 . Severe Hepatic dysfunction ( serum alanine transaminase [ ALT ] , aspartate transaminase [ AST ] , and/or gammaglutamyltransferase [ GGT ] ALL great 2.5 time age sexappropriate ULN ) hepatic impairment ( detectable ascites , serum bilirubin great 2 mg/dL , serum albumin le 3.5 g/dL , prothrombin time prolong 6 second ULN local laboratory absence anticoagulant therapy ) screen first dose study drug 9 . Concomitant spinal cord injury abnormality determine routine imaging : 1 . Conclusive radiological evidence complete spinal cord transection 2 . Multiple injury neurological spinal cord different level 10 . History symptomatic cervical spinal stenosis myelopathy factor confound subject assessment 11 . Unlikely available followup specify protocol 12 . Participated previous clinical study receive investigational product within 30 day screen 13 . Previous exposure SUN13837 14 . Allergy SUN13837 excipients</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>